Syntara (FRA:UUDA) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Syntara Debt-to-Asset?

Syntara's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.10 Mil. Syntara's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Syntara's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €12.97 Mil. Syntara's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Syntara Debt-to-Asset Historical Data

The historical data trend for Syntara's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Debt-to-Asset Chart

Syntara Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.20

0.17

0.16

0.09

0.02

Syntara Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.10	0.09	0.03	0.02	0.01

Competitive Comparison of Syntara's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Syntara's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Syntara Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Syntara's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.092	+	0.052)	/	6.404
	=	0.02

Syntara's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.097	+	0)	/	12.97
	=	0.01

Syntara (FRA:UUDA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Syntara Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Syntara's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (FRA:UUDA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.

Syntara Headlines

No Headlines